<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143874" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Phenazopyridine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>eastham</surname>
            <given-names>john H.</given-names>
          </name>
          <aff>University of the Pacific, Stockton, California</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>john eastham declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143874.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Phenazopyridine, an azo dye, is a urinary analgesic used as an adjuvant medicine in the outpatient setting to&#x000a0;treat patients with urinary tract infections (UTIs) and related conditions (see <bold>Image.</bold> Phenazopyridine Chemical Structure).&#x000a0;Phenazopyridine is approved by the US Food and Drug Administration (FDA) to alleviate symptoms of dysuria, burning sensations, urgency, frequency, and pain linked to lower UTIs. Phenazopyridine is a readily accessible medication that can be obtained over the counter (OTC) and by prescription (see <bold>Image.</bold> Over-the-Counter Phenazopyridine US FDA Labeling). Owing to its analgesic properties, phenazopyridine&#x000a0;can be administered concurrently with antibiotic therapy to relieve patients' pain and enhance their comfort while waiting for effective infection management.&#x000a0;</p>
        <p>This activity reviews phenazopyridine's utilization, mechanism of action, potential adverse effects, off-label applications, dosing, pharmacokinetics, monitoring, and pertinent drug interactions. All healthcare team members involved in the care continuum of patients with UTI and associated disorders can benefit from this activity.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with lower urinary tract infections who could benefit from phenazopyridine as an adjuvant treatment.</p></list-item><list-item><p>Screen patients for contraindications such as severe renal insufficiency and G6PD deficiency before prescribing phenazopyridine.</p></list-item><list-item><p>Implement accurate dosing regimens, aligning phenazopyridine usage with recommended guidelines and patient profiles.</p></list-item><list-item><p>Assess and evaluate patients for potential adverse effects related to phenazopyridine therapy, including urine discoloration and systemic reactions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143874&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143874">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-143874.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Phenazopyridine, an azo dye, is a urinary analgesic used as an adjuvant medicine in the outpatient setting to&#x000a0;treat patients with urinary tract infections (UTIs) and related conditions.&#x000a0;This medication&#x000a0;is approved by the US Food and Drug Administration (FDA). It is used in an outpatient setting to treat patients with dysuria, burning sensations, urgency, frequency, and pain associated with lower UTIs.</p>
        <p>Owing to its analgesic properties, phenazopyridine&#x000a0;can be administered concurrently with antibiotic therapy to relieve patients' pain and enhance their comfort while waiting for effective infection management. Phenazopyridine's analgesic properties can reduce the need for other medications and systemic analgesics. In clinical and inpatient settings, phenazopyridine effectively alleviates trauma, catheter&#x000a0;insertions, and surgical interventions. However, the drug's diagnostic applications are confined in scope.</p>
        <p>
<bold>History of Phenazopyridine</bold>
</p>
        <p>Phenazopyridine was initially synthesized in 1914 and later adopted&#x000a0;by the US Pharmacopoeia in 1928.<xref ref-type="bibr" rid="article-143874.r1">[1]</xref><xref ref-type="bibr" rid="article-143874.r2">[2]</xref> Regulatory mandates did not necessitate preclinical studies to demonstrate the safety and efficacy of medications. Phenazopyridine was commonly prescribed for treating lower UTIs in patients under the mistaken belief that it had bactericidal properties. With the advent of antibiotics in the late 1930s, a definitive curative approach for UTIs was introduced, while phenazopyridine persisted as an adjuvant.<xref ref-type="bibr" rid="article-143874.r1">[1]</xref>&#x000a0;Over the decades, phenazopyridine has been marketed as a standalone drug or combined with antibiotics or other agents.<xref ref-type="bibr" rid="article-143874.r3">[3]</xref></p>
      </sec>
      <sec id="article-143874.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Although the&#x000a0;mechanism of action of phenazopyridine&#x000a0;lacks definitive substantiation, it is hypothesized that the drug exerts a localized analgesic effect on the urinary tract mucosa.<xref ref-type="bibr" rid="article-143874.r1">[1]</xref><xref ref-type="bibr" rid="article-143874.r4">[4]</xref>&#x000a0;Evidence indicates that the drug inhibits nerve fibers in the bladder that respond to mechanical stimuli.<xref ref-type="bibr" rid="article-143874.r5">[5]</xref>&#x000a0;The drug&#x000a0;also hinders kinases responsible for cell growth, metabolism, and nociception.<xref ref-type="bibr" rid="article-143874.r6">[6]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>While the pharmacokinetic characteristics of phenazopyridine are recognized, a comprehensive evaluation of these characteristics is lacking. These characteristics include the following:</p>
        <p><bold>Absorption:</bold> Following oral administration, the drug undergoes rapid absorption in the gastrointestinal tract and reaches a plasma time to peak drug concentration (Tmax) within 2 to 3 hours.<xref ref-type="bibr" rid="article-143874.r7">[7]</xref><xref ref-type="bibr" rid="article-143874.r8">[8]</xref>&#x000a0;Although the exact absorption&#x000a0;site of the drug is unknown, it is believed that there are 2 distinct regions involved.<xref ref-type="bibr" rid="article-143874.r7">[7]</xref> Studies&#x000a0;investigating the half-life of phenazopyridine have yielded inconsistent findings, with 1 study reporting an average half-life of 9.4 hours.<xref ref-type="bibr" rid="article-143874.r8">[8]</xref>&#x000a0;The extent of protein binding is also unknown.</p>
        <p><bold>Metabolism:</bold> Information about the drug's metabolism is derived from animal studies.<xref ref-type="bibr" rid="article-143874.r9">[9]</xref>&#x000a0;Aniline and tri-aminopyridine are the 2&#x000a0;metabolites that could potentially be attributed to hematological and renal adverse events of the drug, respectively.<xref ref-type="bibr" rid="article-143874.r10">[10]</xref><xref ref-type="bibr" rid="article-143874.r11">[11]</xref> Another metabolite of aniline, <italic toggle="yes">N</italic>-acetyl-4-aminophenol, is commonly recognized as acetaminophen and paracetamol. Nonetheless, this metabolite's clinical relevance is considered negligible (see <bold>Image.</bold> Phenazopyridine Metabolism).</p>
        <p><bold>Elimination:</bold>&#x000a0;Research indicates that after administering an oral dose of phenazopyridine, approximately 41% to 65% of the medication is eliminated unchanged by the kidneys.<xref ref-type="bibr" rid="article-143874.r10">[10]</xref><xref ref-type="bibr" rid="article-143874.r9">[9]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-143874.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Adult Dosage, Dosage Forms, and Strengths</bold>
</p>
        <p>Typically, phenazopyridine is prescribed at a dosage of 100 to 200 mg 3 times daily for healthy adults. Over-the-counter (OTC) tablets are obtainable in lower strengths, ranging from 50 to 99.5 mg. The OTC tablets are frequently taken&#x000a0;2 at a time, 3 times daily, effectively matching the prescription regimen. The OTC formulation is a valuable option for temporary symptom relief while awaiting additional medical attention. To prevent stomach discomfort, phenazopyridine is advised to be taken with or after meals.<xref ref-type="bibr" rid="article-143874.r12">[12]</xref>&#x000a0;</p>
        <p>The recommended phenazopyridine&#x000a0;treatment duration is&#x000a0;2 days, and&#x000a0;this short period provides swift relief from discomfort until antibiotics can effectively manage the infection and safeguard the patient from potentially severe adverse effects. Certain clinicians recommend that individuals experiencing uncomplicated UTI symptoms take OTC phenazopyridine alone for 5 days, expecting the infection to resolve spontaneously. However,&#x000a0;most patients favor a more assured resolution, and while the practice is not yet substantiated,&#x000a0;it is noteworthy that a 5-day therapy duration exceeds the current recommendations.</p>
        <p>The drug is commonly used to enhance comfort among outpatients with uncomplicated UTIs. However,&#x000a0;phenazopyridine is not routinely included in treatment protocols for complicated UTIs or inpatient scenarios addressing acute pyelonephritis in patients with risk factors for heightened infection severity.&#x000a0;</p>
        <p>
<bold>Diagnostic use</bold>
</p>
        <p>A study indicates that the oral administration of phenazopyridine with dextrose instillation can effectively facilitate the visualization of ureteral patency during intraoperative cystoscopy.<xref ref-type="bibr" rid="article-143874.r13">[13]</xref> Administering a single 200 mg dose of phenazopyridine&#x000a0;to the patient on the evening&#x000a0;before the&#x000a0;surgical procedure aids in identifying the urethral orifice.<xref ref-type="bibr" rid="article-143874.r14">[14]</xref> However, phenazopyridine is not valuable as a diagnostic tool for detecting incontinence or premature membrane rupture.<xref ref-type="bibr" rid="article-143874.r15">[15]</xref><xref ref-type="bibr" rid="article-143874.r16">[16]</xref></p>
        <p>
<bold>Cystoscopy use</bold>
</p>
        <p>In a randomized controlled trial, 97 patients undergoing cystoscopy received either 200 mg of phenazopyridine along with lidocaine gel or lidocaine gel alone. The&#x000a0;medications were administered in&#x000a0;3 doses, starting with a dose administered 20 minutes&#x000a0;before&#x000a0;the procedure and then every 8 hours thereafter.&#x000a0;Participants who were administered phenazopyridine and lidocaine gel reported experiencing less discomfort and exhibited lower heart rates than those who received only lidocaine gel. The authors concluded that phenazopyridine reduces the intensity of pain associated with both cystoscopy and the initial act of urination.<xref ref-type="bibr" rid="article-143874.r17">[17]</xref></p>
        <p>
<bold>Postoperative use</bold>
</p>
        <p>In a randomized controlled study involving 152 women undergoing prolapse surgery, administering a single postoperative dose of phenazopyridine at 200 mg did not demonstrate enhanced postoperative voiding compared to the control group.<xref ref-type="bibr" rid="article-143874.r18">[18]</xref> In a retrospective cohort study involving 149 women who underwent a retropubic mid-urethral sling operation, phenazopyridine was reported to improve postoperative voiding.<xref ref-type="bibr" rid="article-143874.r19">[19]</xref></p>
        <p>
<bold>Radiation-induced cystitis use</bold>
</p>
        <p>Phenazopyridine has been used safely for up to&#x000a0;2 months as a form of supportive care in cases of radiation-induced cystitis.<xref ref-type="bibr" rid="article-143874.r20">[20]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Renal impairment<bold>:</bold> For individuals with mild renal impairment, with a glomerular filtration rate of more than 50 mL/min, the recommended dosing frequency is every 8 to 16 hours. Phenazopyridine should not used in patients with a glomerular filtration rate of less than 50 mL/min.<xref ref-type="bibr" rid="article-143874.r21">[21]</xref></p>
        <p>Hepatic impairment:&#x000a0;Phenazopyridine is contraindicated in cases of severe hepatitis.</p>
        <p>Pregnancy considerations: Phenazopyridine is an FDA pregnancy category B drug known to cross the placenta.<xref ref-type="bibr" rid="article-143874.r16">[16]</xref> Phenazopyridine should be used in pregnancy only if it is indicated.&#x000a0;</p>
        <p>Breastfeeding considerations:&#x000a0;The safety of phenazopyridine is not established during breastfeeding. Therefore, phenazopyridine is not recommended during lactation due to its potential to cause methemoglobinemia and hemolytic anemia, especially in infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency.<xref ref-type="bibr" rid="article-143874.r22">[22]</xref></p>
        <p>Pediatric considerations: The recommended dosage for children aged 6 to 12 is 12 mg/kg/d, divided into 3 equal doses. A specialized pediatric formulation is not commercially available and requires compounding.<xref ref-type="bibr" rid="article-143874.r23">[23]</xref>&#x000a0;Although review articles and consensus publications addressing the treatment of pediatric UTIs exist, they do not typically reference the use of phenazopyridine.<xref ref-type="bibr" rid="article-143874.r24">[24]</xref><xref ref-type="bibr" rid="article-143874.r25">[25]</xref></p>
        <p>Older patients: It is advised to consult renal dosing guidelines for older patients.</p>
        <p>
<bold>Clinical Studies</bold>
</p>
        <p>Phenazopyridine was marketed before the implementation of regulations that mandated preclinical studies to establish a drug's safety and efficacy. Consequently, comprehensive and substantial studies are lacking, and the drug's role in UTI treatment primarily relies on clinical observations.</p>
        <p>A critical analysis of the available studies has been published. Among these studies, 1 encompassed 118 patients, of which 64% of the participants had cystitis or pyelonephritis. All participants were administered phenazopyridine at 200 mg, 3 times daily, for 2 weeks, exceeding the recommended duration. The analysis was conducted as an open-label, single-arm study. The authors documented enhanced symptomatic responses, including alleviation of dysuria (95.3%), burning sensation (93.6%), frequency (85.6%), and nocturia (83.7%).<xref ref-type="bibr" rid="article-143874.r1">[1]</xref></p>
        <p>Another investigation involved 49 subjects with acute UTIs who received phenazopyridine at a dosage of 200 mg administered 3 times daily. After 24 and 72 hours, patients underwent evaluations for nocturia, burning, and urgency symptoms. Mean symptom scores were reported as slight, with 3 or 4 symptoms after 24 hours and none, with 1 or 2 after 72 hours.<xref ref-type="bibr" rid="article-143874.r26">[26]</xref></p>
        <p>Phenazopyridine was compared to flavoxate, an antispasmodic drug, in a study involving 392 participants displaying UTI symptoms, incontinence, and/or suprapubic pain. The participants were administered either phenazopyridine at a dosage of 200 mg 3 times daily or flavoxate at a dosage of 100 mg 4 times daily. The variances in clinical response did not demonstrate statistical significance.&#x000a0;In a separate analysis of men with prostatitis, the participants were subjected to a regimen of phenazopyridine at a dosage of 200 mg 3 times daily. Only 31% of the subjects reported satisfactory relief from symptoms.<xref ref-type="bibr" rid="article-143874.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-143874.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Phenazopyridine has a good safety profile, with infrequent occurrences of severe adverse events. Severe and potentially life-threatening adverse effects are generally confined to instances of overdose, preexisting renal insufficiency, and surpassing the recommended dosing and duration guidelines.<xref ref-type="bibr" rid="article-143874.r27">[27]</xref><xref ref-type="bibr" rid="article-143874.r28">[28]</xref></p>
        <p>The common adverse drug reactions of phenazopyridine&#x000a0;have been listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system: Headache</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dermatological: Rash, discoloration, pruritus, and ulceration&#x000a0;<xref ref-type="bibr" rid="article-143874.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity: Anaphylactoid-like reaction or hypersensitivity hepatitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal: Nausea, vomiting, and diarrhea</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hematological:&#x000a0;Methemoglobinemia, sulfhemoglobinemia, and hemolytic anemia (may act as a potential hemolytic agent in G6PD deficiency) <xref ref-type="bibr" rid="article-143874.r30">[30]</xref><xref ref-type="bibr" rid="article-143874.r31">[31]</xref><xref ref-type="bibr" rid="article-143874.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal: Acute interstitial nephritis&#x000a0;<xref ref-type="bibr" rid="article-143874.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other effects: Discoloration of body fluids, aseptic meningitis, visual disturbances, renal or hepatic toxicity associated with overdose, jaundice, and renal calculi&#x000a0;<xref ref-type="bibr" rid="article-143874.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>The drug is recognized for its potential to induce methemoglobinemia and hemolytic anemia, which is thought to occur via a metabolite, aniline. In cases of hemolytic anemia, a microscopic examination of red blood cells reveals the presence of Heinz bodies and degmacytes (bite cells).<xref ref-type="bibr" rid="article-143874.r34">[34]</xref>&#x000a0;</p>
        <p>The treatment for drug-induced hemolytic anemia involves discontinuing the causative agent and contemplating the utilization of corticosteroids.<xref ref-type="bibr" rid="article-143874.r35">[35]</xref> Interstitial nephritis may manifest following an overdose, and cases have been reported even with therapeutic doses and in individuals with normal renal function.<xref ref-type="bibr" rid="article-143874.r33">[33]</xref> In instances of phenazopyridine-induced nephrotoxicity, the use of roentgenographic contrast media may exacerbate renal damage.<xref ref-type="bibr" rid="article-143874.r36">[36]</xref>&#x000a0;</p>
        <p>Cases of hepatitis appear to be associated with dose-related hypersensitivity.<xref ref-type="bibr" rid="article-143874.r37">[37]</xref><xref ref-type="bibr" rid="article-143874.r38">[38]</xref><bold>&#x000a0;</bold>Other infrequent adverse effects, such as thrombocytopenia and allergic-like skin reactions, have also been reported.<xref ref-type="bibr" rid="article-143874.r39">[39]</xref><xref ref-type="bibr" rid="article-143874.r40">[40]</xref></p>
      </sec>
      <sec id="article-143874.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Individuals&#x000a0;with known hypersensitivity to phenazopyridine should avoid taking the medication. Furthermore, phenazopyridine is contraindicated in severe renal insufficiency, with a glomerular filtration rate below 50 mL/min. Patients with severe hepatitis are advised not to take the drug due to contraindications.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>Patients with known G6PD deficiency are more susceptible to hemolysis and should avoid receiving phenazopyridine.<xref ref-type="bibr" rid="article-143874.r30">[30]</xref>&#x000a0;In addition, the drug should be administered cautiously in cases of impaired hepatic function.</p>
        <p>
<bold>Carcinogenicity</bold>
</p>
        <p>Rats subjected to phenazopyridine exhibited the development of liver and colorectal tumors, encompassing both malignant and benign growths. However, no established correlation exists between human phenazopyridine usage and carcinogenicity (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ntp.niehs.nih.gov/ntp/roc/content/profiles/phenazopyridinehydrochloride.pdf">15th Report on Carcinogens, National Toxicology Program, 2021</ext-link>).</p>
        <p>
<bold>Interactions</bold>
</p>
        <p>Phenazopyridine has no known drug-drug or drug-food interactions. Due to its dye properties,&#x000a0;phenazopyridine is anticipated to interfere with urinalysis tests that rely on color reactions or spectrometry. Theoretically, there might be a heightened risk of methemoglobinemia when phenazopyridine is combined with a local anesthetic such as benzocaine. However, this potential risk lacks confirmation in medical literature, as the drug has been effectively employed alongside lidocaine gel.<xref ref-type="bibr" rid="article-143874.r17">[17]</xref></p>
      </sec>
      <sec id="article-143874.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Because phenazopyridine is available as an OTC product, there is the possibility of incorrect drug usage. Effective patient education is of utmost importance while using the medication.<xref ref-type="bibr" rid="article-143874.r41">[41]</xref>&#x000a0;Healthcare providers should instruct&#x000a0;patients that phenazopyridine is not an antibiotic but provides only symptomatic relief.<xref ref-type="bibr" rid="article-143874.r42">[42]</xref></p>
        <p>Although some uncomplicated lower UTIs might resolve spontaneously and even achieve a bacteriological cure, the overall cure rate remains relatively low. Research findings have established that appropriate antibiotic treatment leads to quicker symptom resolution and a higher likelihood of bacteriological cure than a placebo.<xref ref-type="bibr" rid="article-143874.r43">[43]</xref><xref ref-type="bibr" rid="article-143874.r44">[44]</xref> In cases where an antibiotic is prescribed, phenazopyridine enhances comfort while the antibiotic works to eliminate the causative bacteria.</p>
        <p>In 2 surveys conducted in Los Angeles County, 71% of OTC phenazopyridine consumers were unaware that a bladder infection or another type of UTI caused their symptoms. Furthermore, 38% reported purchasing the drug as a substitute for medical care.<xref ref-type="bibr" rid="article-143874.r45">[45]</xref><xref ref-type="bibr" rid="article-143874.r46">[46]</xref></p>
        <p>Due to its dye properties, phenazopyridine causes a noticeable change in urine color, turning it reddish-orange (see <bold>Image.</bold> Urine Colored With Phenazopyridine). Patients should receive counseling about this effect to address concerns proactively. They should be informed that the alteration in their urine color results from the drug's color and does not indicate bleeding. Spilled urine can potentially cause staining, particularly on clothing. Extended use beyond appropriate limits may lead to a yellowing of the skin and the sclera of the eyes. The drug is also reported to affect the color of tears and ejaculate, potentially leading to the staining of contact lenses. Patients should also promptly report any urinary tract symptoms that do not improve or worsen.<xref ref-type="bibr" rid="article-143874.r23">[23]</xref><xref ref-type="bibr" rid="article-143874.r41">[41]</xref></p>
      </sec>
      <sec id="article-143874.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The occurrence of phenazopyridine-induced methemoglobinemia is rare, with fewer than 50 cases being documented since 1951. The National Poison Data System Study conducted in 2020 investigated patients from 2007 to 2017 to identify the substances frequently associated with methemoglobinemia. The study underscores that phenazopyridine is linked to a notable number of reported cases of methemoglobinemia.<xref ref-type="bibr" rid="article-143874.r47">[47]</xref><bold>&#x000a0;</bold></p>
        <p>Methemoglobinemia can be managed using standard treatments, including methylene blue, the preferred antidote. This medication is administered intravenously as a 1% solution at a dose of 1 to 2 mg/kg as required. Methylene blue should not be administered to patients with known or suspected G6PD deficiency and those taking antidepressants, as it can elevate the risk of serotonin syndrome.<xref ref-type="bibr" rid="article-143874.r48">[48]</xref>&#x000a0;</p>
        <p>In such scenarios, the recommended alternative antidote is intravenous high-dose ascorbic acid. Research has elucidated the reasons why phenazopyridine and other drugs, such as dapsone and chloroquine, more commonly induce methemoglobinemia compared to other medications. Oxidative Heinz body hemolytic anemia may also be triggered, and chronic overdosage incidents can manifest with bite cells, also known as degmacytes.</p>
        <p>In cases of drug overdose, patients can experience renal toxicity, occasional renal failure, and hepatic impairment.<xref ref-type="bibr" rid="article-143874.r49">[49]</xref>&#x000a0;Although the mechanism behind renal toxicity remains unclear, there is a possibility that a metabolite known as triaminopyridine might damage the distal renal tubules.<xref ref-type="bibr" rid="article-143874.r11">[11]</xref> Life-threatening adverse effects, including hemolytic anemia and renal failure, have been associated with inappropriate OTC phenazopyridine use and intentional drug overdose.<xref ref-type="bibr" rid="article-143874.r50">[50]</xref><xref ref-type="bibr" rid="article-143874.r51">[51]</xref></p>
      </sec>
      <sec id="article-143874.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to its availability as an&#x000a0;OTC product, there exists the potential for inappropriate use of phenazopyridine. Therefore, gathering information on both OTC and prescription drugs is imperative when conducting medication reviews.<xref ref-type="bibr" rid="article-143874.r51">[51]</xref></p>
        <p>The interprofessional healthcare team should collaborate to deliver comprehensive patient education. Opting for treatment with an appropriate antibiotic leads to significantly faster symptom relief and the elimination of the infection Clinicians may consider prescribing phenazopyridine to alleviate the sensations of burning, urgency, frequency, and pain linked to lower UTIs, potentially for a brief duration of 2 days until the antibiotic effectively eliminates the causative bacteria Continued use beyond 2 days could impede the timely diagnosis and initiation of appropriate treatment. Hence, patients must understand&#x000a0;that phenazopyridine does not possess any anti-infective properties.</p>
        <p>Healthcare providers&#x000a0;should verify the accuracy of the dosage before administering it to patients and counsel&#x000a0;them regarding the extended treatment duration, which heightens the risk of severe adverse effects. Patients should also&#x000a0;be informed about urine color changes to prevent unnecessary alarm when they observe this alteration.</p>
        <p>Pharmacists&#x000a0;are critical in educating patients that phenazopyridine solely offers symptomatic relief and, therefore, should not serve as a substitute for seeking medical attention. Instead, patients should collaborate with their medical providers, sharing any observations or concerns about their medication regimen. Promoting open communication and fostering collaborative efforts among all interprofessional healthcare team members enhances patient safety and optimize treatment outcomes when utilizing phenazopyridine.</p>
      </sec>
      <sec id="article-143874.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143874&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143874">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143874/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143874">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-143874.s11">
        <fig id="article-143874.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Phenazopyridine Chemical Structure Contributed by John H Eastham, Pharm D, MA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenazopyridine__chemical__structure" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-143874.s12">
        <fig id="article-143874.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Phenazopyridine Metabolism Contributed by John H Eastham, Pharm D, MA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Phenazopyridine__metabolism" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-143874.s13">
        <fig id="article-143874.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Over-the-Counter Phenazopyridine US FDA Labeling Contributed by John H Eastham, Pharm D, MA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="OTC__phenazopyridine__U.S.__FDA__labeling" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-143874.s14">
        <fig id="article-143874.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Urine Colored With Phenazopyridine Contributed by John H Eastham, Pharm D, MA</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Urine__colored__with__Phenazopyridine__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-143874.s15">
        <title>References</title>
        <ref id="article-143874.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zelenitsky</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Zhanel</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine in urinary tract infections.</article-title>
            <source>Ann Pharmacother</source>
            <year>1996</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>7-8</issue>
            <fpage>866</fpage>
            <page-range>866-8</page-range>
            <pub-id pub-id-type="pmid">8826573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgue&#x000f1;o-Tapia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mora-P&#x000e9;rez</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morales-R&#x000ed;os</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Joseph-Nathan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>1H, 13C and 15N NMR assignments of phenazopyridine derivatives.</article-title>
            <source>Magn Reson Chem</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>256</fpage>
            <page-range>256-60</page-range>
            <pub-id pub-id-type="pmid">15625718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SPINELLI</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>KESHIN</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>DAVIS</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>A NEW MEDICATION FOR RELIEF OF URINARY SYMPTOMS: A PRELIMINARY REPORT.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>1964</year>
            <month>Aug</month>
            <volume>12</volume>
            <fpage>771</fpage>
            <page-range>771-5</page-range>
            <pub-id pub-id-type="pmid">14197867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onder</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Espinoza</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Berho</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Chandar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zilleruelo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abitbol</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acute renal failure due to phenazopyridine (Pyridium) overdose: case report and review of the literature.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1760</fpage>
            <page-range>1760-4</page-range>
            <pub-id pub-id-type="pmid">16897003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preynat-Seauve</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Westermaier</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>H&#x000e9;ritier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tardy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cambet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feyeux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caillon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scapozza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Novel Mechanism for an Old Drug: Phenazopyridine is a Kinase Inhibitor Affecting Autophagy and Cellular Differentiation.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>664608</fpage>
            <pub-id pub-id-type="pmid">34421588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aizawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wyndaele</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of phenazopyridine on rat bladder primary afferent activity, and comparison with lidocaine and acetaminophen.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>1445</fpage>
            <page-range>1445-50</page-range>
            <pub-id pub-id-type="pmid">20976818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Determination of phenazopyridine in human plasma via LC-MS and subsequent development of a pharmacokinetic model.</article-title>
            <source>Anal Bioanal Chem</source>
            <year>2005</year>
            <month>May</month>
            <volume>382</volume>
            <issue>1</issue>
            <fpage>216</fpage>
            <page-range>216-22</page-range>
            <pub-id pub-id-type="pmid">15900475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Determination of phenazopyridine in human plasma by GC-MS and its pharmacokinetics.</article-title>
            <source>J Chromatogr Sci</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>686</fpage>
            <page-range>686-9</page-range>
            <pub-id pub-id-type="pmid">18796223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitr&#x000e8;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maffei-Facino</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Isolation and identification of two hydroxylated metabolites of phenazopyridine in rat urine.</article-title>
            <source>Farmaco Sci</source>
            <year>1977</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>453</fpage>
            <page-range>453-60</page-range>
            <pub-id pub-id-type="pmid">872925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Chartrand</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The metabolism and excretion of phenazopyridine hydrochloride in animals and man.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>1976</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>371</fpage>
            <page-range>371-6</page-range>
            <pub-id pub-id-type="pmid">982458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomlinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxicity of phenazopyridine.</article-title>
            <source>Hum Toxicol</source>
            <year>1983</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>539</fpage>
            <page-range>539-43</page-range>
            <pub-id pub-id-type="pmid">6885099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gould</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Urinary tract disorders. Clinical comparison of flavoxate and phenazopyridine.</article-title>
            <source>Urology</source>
            <year>1975</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>612</fpage>
            <page-range>612-5</page-range>
            <pub-id pub-id-type="pmid">1093308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Askew</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Dieter</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Cost-effectiveness of agents used for evaluation of ureteral patency during intraoperative cystoscopy in gynecologic and urogynecologic surgery.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>226</volume>
            <issue>1</issue>
            <fpage>100.e1</fpage>
            <page-range>100.e1-100.e6</page-range>
            <pub-id pub-id-type="pmid">34487702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehfuss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sorokin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine: A Preoperative Way to Identify Ureteral Orifices.</article-title>
            <source>Urology</source>
            <year>2018</year>
            <month>May</month>
            <volume>115</volume>
            <fpage>36</fpage>
            <page-range>36-38</page-range>
            <pub-id pub-id-type="pmid">29501712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wall</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>The Pyridium pad test for diagnosing urinary incontinence. A comparative study of asymptomatic and incontinent women.</article-title>
            <source>J Reprod Med</source>
            <year>1990</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>682</fpage>
            <page-range>682-4</page-range>
            <pub-id pub-id-type="pmid">2198349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Gonik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Creasy</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of phenazopyridine hydrochloride as a tool in the diagnosis of premature rupture of the membranes.</article-title>
            <source>Am J Perinatol</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>297</fpage>
            <page-range>297-9</page-range>
            <pub-id pub-id-type="pmid">1760061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsukanov</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Makushin</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Mirzakadiev</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zolotov</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>[Influence of phenazopyridine on the well-being of patients during and after cystoscopy].</article-title>
            <source>Urologiia</source>
            <year>2020</year>
            <month>Sep</month>
            <issue>4</issue>
            <fpage>50</fpage>
            <page-range>50-54</page-range>
            <pub-id pub-id-type="pmid">32897014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sierra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Phenazopyridine on Immediate Postoperative Voiding After Prolapse Surgery: A Randomized Controlled Trial.</article-title>
            <source>Female Pelvic Med Reconstr Surg</source>
            <year>2021</year>
            <month>Feb</month>
            <day>01</day>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-89</page-range>
            <pub-id pub-id-type="pmid">31033527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Due&#x000f1;as-Garcia</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Sierra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nicasio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Preoperative Phenazopyridine on Urinary Retention Following Midurethral Sling.</article-title>
            <source>Female Pelvic Med Reconstr Surg</source>
            <year>2018</year>
            <season>Jan/Feb</season>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-47</page-range>
            <pub-id pub-id-type="pmid">28230566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shore</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Britnell</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Safety analysis of long-term phenazopyridine use for radiation cystitis.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>306</fpage>
            <page-range>306-311</page-range>
            <pub-id pub-id-type="pmid">31006341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bennett</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Muther</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Golper</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics.</article-title>
            <source>Ann Intern Med</source>
            <year>1980</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-89</page-range>
            <pub-id pub-id-type="pmid">6994534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Phenazopyridine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaines</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine hydrochloride: the use and abuse of an old standby for UTI.</article-title>
            <source>Urol Nurs</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-9</page-range>
            <pub-id pub-id-type="pmid">15311491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buettcher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trueck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Niederer-Loher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heininger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Agyeman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Asner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bielicki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kahlert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kottanattu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meyer Sauteur</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Paioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Posfay-Barbe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Relly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zucol</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gobet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shavit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rudin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Laube</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>von Vigier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Swiss consensus recommendations on urinary tract infections in children.</article-title>
            <source>Eur J Pediatr</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>180</volume>
            <issue>3</issue>
            <fpage>663</fpage>
            <page-range>663-674</page-range>
            <pub-id pub-id-type="pmid">32621135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattoo</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Contemporary Management of Urinary Tract Infection in Children.</article-title>
            <source>Pediatrics</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>147</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33479164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trickett</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Ancillary use of phenazopyridine (Pyridium) in urinary tract infections.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>1970</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>441</fpage>
            <page-range>441-5</page-range>
            <pub-id pub-id-type="pmid">4990290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Doddabele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karnad</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Chronic severe hemolytic anemia related to surreptitious phenazopyridine abuse.</article-title>
            <source>Ann Intern Med</source>
            <year>1994</year>
            <month>Aug</month>
            <day>15</day>
            <volume>121</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <pub-id pub-id-type="pmid">8037417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Bovasso</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Acquired methemoglobinemia and hemolytic anemia following excessive pyridium (phenazopyridine hydrochloride) ingestion.</article-title>
            <source>Clin Pediatr (Phila)</source>
            <year>1971</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>537</fpage>
            <page-range>537-40</page-range>
            <pub-id pub-id-type="pmid">5095165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zarei</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tavanaee Sani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elyasi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Skin ulcers as a complication of short-term use of phenazopyridine in an old man: A case report.</article-title>
            <source>J Infect Chemother</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>1654</fpage>
            <page-range>1654-1657</page-range>
            <pub-id pub-id-type="pmid">35963601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>GABOR</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>LOWENSTEIN</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>DE LEEUW</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>HEMOLYTIC ANEMIA INDUCED BY PHENYLAZO-DIAMINO-PYRIDINE (PYRIDIUM).</article-title>
            <source>Can Med Assoc J</source>
            <year>1964</year>
            <month>Oct</month>
            <day>03</day>
            <volume>91</volume>
            <issue>14</issue>
            <fpage>756</fpage>
            <page-range>756-9</page-range>
            <pub-id pub-id-type="pmid">14215217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christensen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Protracted methemoglobinemia after phenazopyridine overdose in an infant.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>112</fpage>
            <page-range>112-6</page-range>
            <pub-id pub-id-type="pmid">8852386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakraborty</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Filshie</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Methaemoglobinaemia produced by phenazopyridine (Pyridium) in a man with chronic obstructive airways disease.</article-title>
            <source>Scott Med J</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>185</fpage>
            <page-range>185-6</page-range>
            <pub-id pub-id-type="pmid">3449947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shailesh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine associated acute interstitial nephritis and review of literature.</article-title>
            <source>Ren Fail</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>804</fpage>
            <page-range>804-7</page-range>
            <pub-id pub-id-type="pmid">24575779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberg</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Heinz body hemolytic animea. "Bite cells" -a clue to diagnosis.</article-title>
            <source>Arch Intern Med</source>
            <year>1976</year>
            <month>Feb</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-5</page-range>
            <pub-id pub-id-type="pmid">1247346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosselet</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hemolytic anemia: Pharmacological aspects.</article-title>
            <source>Transfus Clin Biol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>110</fpage>
            <page-range>110-114</page-range>
            <pub-id pub-id-type="pmid">28648734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engle</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schoolwerth</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Additive nephrotoxicity from roentgenographic contrast media. Its occurrence in phenazopyridine-induced acute renal failure.</article-title>
            <source>Arch Intern Med</source>
            <year>1981</year>
            <month>May</month>
            <volume>141</volume>
            <issue>6</issue>
            <fpage>784</fpage>
            <page-range>784-6</page-range>
            <pub-id pub-id-type="pmid">7235788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badley</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine-induced hepatitis.</article-title>
            <source>Br Med J</source>
            <year>1976</year>
            <month>Oct</month>
            <day>09</day>
            <volume>2</volume>
            <issue>6040</issue>
            <fpage>850</fpage>
            <pub-id pub-id-type="pmid">990717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldfinger</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity hepatitis due to phenazopyridine hydrochloride.</article-title>
            <source>N Engl J Med</source>
            <year>1972</year>
            <month>May</month>
            <day>18</day>
            <volume>286</volume>
            <issue>20</issue>
            <fpage>1090</fpage>
            <page-range>1090-1</page-range>
            <pub-id pub-id-type="pmid">5018866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilde</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Prentice</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Sulfamethoxazole-phenazopyridine and thrombocytopenia.</article-title>
            <source>Ann Intern Med</source>
            <year>1986</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-9</page-range>
            <pub-id pub-id-type="pmid">3940493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeung</surname>
                <given-names>WWY</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CSM</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Delayed-type drug eruption to phenazopyridine (pyridium) confirmed with patch testing.</article-title>
            <source>Asia Pac Allergy</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>e10</fpage>
            <pub-id pub-id-type="pmid">35174061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornwell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bartek</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine hydrochloride: information for patient teaching.</article-title>
            <source>Urol Nurs</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>153</fpage>
            <page-range>153-4</page-range>
            <pub-id pub-id-type="pmid">9258059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <article-title>Urinary tract infection drug helps pain, hinders cure.</article-title>
            <source>Health News</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">15551462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferry</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Stenlund</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lundholm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Monsen</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.</article-title>
            <source>Scand J Prim Health Care</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">17354160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kotsantis</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Vouloumanou</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Rafailidis</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials.</article-title>
            <source>J Infect</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-102</page-range>
            <pub-id pub-id-type="pmid">19195714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Asch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fielder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Consumer knowledge of over-the-counter phenazopyridine.</article-title>
            <source>Ann Fam Med</source>
            <year>2004</year>
            <season>May-Jun</season>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>240</fpage>
            <page-range>240-4</page-range>
            <pub-id pub-id-type="pmid">15209201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Asch</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fielder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gelberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Leake</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Usage patterns of over-the-counter phenazopyridine (pyridium).</article-title>
            <source>J Gen Intern Med</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-7</page-range>
            <pub-id pub-id-type="pmid">12709095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wills</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Cumpston</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Causative Agents in Clinically Significant Methemoglobinemia: A National Poison Data System Study.</article-title>
            <source>Am J Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <day>29</day>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>e548</fpage>
            <page-range>e548-e551</page-range>
            <pub-id pub-id-type="pmid">33416248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nasrullah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>DiSilvio</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Phenazopyridine-Induced Methaemoglobinaemia The Aftermath of Dysuria Treatment.</article-title>
            <source>Eur J Case Rep Intern Med</source>
            <year>2022</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>003191</fpage>
            <pub-id pub-id-type="pmid">35265556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hood</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>WN</given-names>
              </name>
            </person-group>
            <article-title>Jaundice caused by phenazopyridine hydrochloride.</article-title>
            <source>JAMA</source>
            <year>1966</year>
            <month>Dec</month>
            <day>26</day>
            <volume>198</volume>
            <issue>13</issue>
            <fpage>1366</fpage>
            <page-range>1366-7</page-range>
            <pub-id pub-id-type="pmid">5953726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vega</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Acute renal failure caused by phenazopyridine].</article-title>
            <source>Rev Med Chil</source>
            <year>2003</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>541</fpage>
            <page-range>541-4</page-range>
            <pub-id pub-id-type="pmid">12879816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143874.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheurer</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>An over-the-counter omission.</article-title>
            <source>South Med J</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>99</volume>
            <issue>9</issue>
            <fpage>1005</fpage>
            <page-range>1005-6</page-range>
            <pub-id pub-id-type="pmid">17004539</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
